{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T06:25:03Z","timestamp":1776839103117,"version":"3.51.2"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.jacl.2017.12.014","type":"journal-article","created":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T18:21:03Z","timestamp":1514917263000},"page":"409-416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapy"],"prefix":"10.1016","volume":"12","author":[{"given":"Annette M.","family":"Galema-Boers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattie J.","family":"Lenzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie R.","family":"Engelkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J.","family":"Sijbrands","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanine E.","family":"Roeters van Lennep","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2017.12.014_bib1","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2017.12.014_bib2","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S0140-6736(69)90930-1","article-title":"Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states","volume":"2","author":"Slack","year":"1969","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2017.12.014_bib3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/aje\/kwh237","article-title":"Familial hypercholesterolemia and coronary heart disease: a HuGE association review","volume":"160","author":"Austin","year":"2004","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jacl.2017.12.014_bib4","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2017.12.014_bib5","doi-asserted-by":"crossref","first-page":"a2423","DOI":"10.1136\/bmj.a2423","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long term cohort study","volume":"337","author":"Versmissen","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2017.12.014_bib6","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/bmj.303.6807.893","article-title":"Risk of fatal coronary heart disease in familial hypercholesterolaemia","volume":"303","year":"1991","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2017.12.014_bib7","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","volume":"253","author":"Catapano","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2017.12.014_bib8","first-page":"2245","article-title":"European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk","volume":"38","author":"Landmesser","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2017.12.014_bib9","series-title":"Resource Impact Report: alirocumab (TA393) and evolocumab (TA394) for treating primary hypercholesterolaemia and mixed dyslipidaemia","first-page":"1","author":"NICE NIfHaCE","year":"2016"},{"key":"10.1016\/j.jacl.2017.12.014_bib10","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/eurheartj\/eht015","article-title":"Diagnosis and treatment of familial hypercholesterolaemia","volume":"34","author":"Hovingh","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2017.12.014_bib11","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"issue":"Suppl 2","key":"10.1016\/j.jacl.2017.12.014_bib12","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1097\/01.hjr.0000277984.31558.c4","volume":"14","author":"Graham","year":"2007","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"10.1016\/j.jacl.2017.12.014_bib13","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2017.12.014_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/08037051.2014.868629","article-title":"2013 ESH\/ESC Practice Guidelines for the Management of Arterial Hypertension","volume":"23","author":"Mancia","year":"2014","journal-title":"Blood Press"},{"issue":"Suppl 1","key":"10.1016\/j.jacl.2017.12.014_bib15","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.2337\/dc12-s064","article-title":"Diagnosis and classification of diabetes mellitus","volume":"35","author":"American Diabetes Association","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2017.12.014_bib16","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/bmj.39339.610000.BE","article-title":"The declaration of Helsinki","volume":"335","author":"Goodyear","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2017.12.014_bib17","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2009.09.014","article-title":"Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands","volume":"209","author":"Pijlman","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2017.12.014_bib18","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.atherosclerosis.2013.12.020","article-title":"Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers","volume":"233","author":"Besseling","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2017.12.014_bib19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.atherosclerosis.2007.12.024","article-title":"Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors","volume":"200","author":"Alonso","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2017.12.014_bib20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jacc.2016.04.054","article-title":"Statins in Familial Hypercholesterolemia: Consequences for Coronary Artery Disease and All-Cause Mortality","volume":"68","author":"Besseling","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2017.12.014_bib21","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa1605086","article-title":"Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease","volume":"375","author":"Khera","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2017.12.014_bib22","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/bmj.322.7293.1019","article-title":"Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study","volume":"322","author":"Sijbrands","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2017.12.014_bib23","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2796.2004.01405.x","article-title":"The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients","volume":"256","author":"Jansen","year":"2004","journal-title":"J Intern Med"},{"key":"10.1016\/j.jacl.2017.12.014_bib24","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/2047487315569401","article-title":"EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries","volume":"23","author":"Kotseva","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2017.12.014_bib25","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1136\/heartjnl-2013-303989","article-title":"Effect of a nurse-coordinated prevention programme on cardiovascular risk after an acute coronary syndrome: main results of the RESPONSE randomised trial","volume":"99","author":"Jorstad","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.jacl.2017.12.014_bib26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijcard.2013.11.025","article-title":"Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation","volume":"171","author":"Watts","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacl.2017.12.014_bib27","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jacc.2017.05.041","article-title":"Community-Based Lifestyle Intervention in Patients With Coronary Artery Disease: The RESPONSE-2 Trial","volume":"70","author":"Minneboo","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2017.12.014_bib28","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00228-013-1640-3","article-title":"Predicting non-adherence in patients with familial hypercholesterolemia","volume":"70","author":"Galema-Boers","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jacl.2017.12.014_bib29","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2174\/0929867324666170112111948","article-title":"Lipoprotein (a) and Cardiovascular Risk: The Show Must go on","volume":"24","author":"Katsiki","year":"2017","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jacl.2017.12.014_bib30","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1093\/eurheartj\/ehx546","article-title":"Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a)","volume":"38","author":"Vuorio","year":"2017","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jacl.2017.12.014_bib31","first-page":"CD011748","article-title":"PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease","author":"Schmidt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacl.2017.12.014_bib32","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2017.12.014_bib33","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","article-title":"Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg\/dl or Higher","volume":"30","author":"Ginsberg","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacl.2017.12.014_bib34","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2017.12.014_bib35","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.2016.11004","article-title":"Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease","volume":"316","author":"Kazi","year":"2016","journal-title":"JAMA"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287417305494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287417305494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T23:55:58Z","timestamp":1535154958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287417305494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S1933287417305494"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2017.12.014","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2017.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 National Lipid Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}